Emanuela Palmerini

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. pmc The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
    Emanuela Palmerini
    Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
    Eur J Nucl Med Mol Imaging 44:215-223. 2017
  2. pmc Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
    E Palmerini
    PROMETEO Laboratory Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy
    BMC Cancer 16:280. 2016
  3. doi request reprint Nonresectable multiple lung metastases of high-grade osteosarcoma of the humerus: stable after twelve years. A case report
    Emanuela Palmerini
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, Italy
    J Bone Joint Surg Am 90:2240-4. 2008
  4. doi request reprint Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution
    Emanuela Palmerini
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 115:2988-98. 2009
  5. pmc Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
  6. ncbi request reprint Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study
    Stefano Ferrari
    Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 96:213-8. 2010
  7. doi request reprint Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:908-12. 2008
  8. doi request reprint Periosteal osteosarcoma: a single-institution experience
    Marilena Cesari
    Chemotherapy Section, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 117:1731-5. 2011
  9. doi request reprint Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years
    Stefano Ferrari
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, Italy
    Tumori 98:702-8. 2012
  10. doi request reprint Local and systemic control of Ewing's bone sarcoma family tumors of the ribs
    Antonio Briccoli
    Unit of General Surgery, Istituto Ortopedico Rizzoli, Bologna 40136, Italy
    J Surg Oncol 100:222-6. 2009

Collaborators

Detail Information

Publications30

  1. pmc The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
    Emanuela Palmerini
    Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
    Eur J Nucl Med Mol Imaging 44:215-223. 2017
    ....
  2. pmc Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
    E Palmerini
    PROMETEO Laboratory Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy
    BMC Cancer 16:280. 2016
    ..Few new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS)...
  3. doi request reprint Nonresectable multiple lung metastases of high-grade osteosarcoma of the humerus: stable after twelve years. A case report
    Emanuela Palmerini
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, Italy
    J Bone Joint Surg Am 90:2240-4. 2008
  4. doi request reprint Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution
    Emanuela Palmerini
    Department of Chemotherapy, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 115:2988-98. 2009
    ..The optimal treatment for synovial sarcoma remains controversial. Treatment, outcome, and prognostic factors in patients treated in a single institution were examined...
  5. pmc Fibrosarcomatous changes and expression of CD34+ and apolipoprotein-D in dermatofibrosarcoma protuberans
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Clin Sarcoma Res 2:4. 2012
    ..A more aggressive appearing fibrosarcoma may arise in DFSP, changing its biological behavior. CD34 and apolipoprotein-D are highly expressed in DFSP, but their prognostic significance is uncertain...
  6. ncbi request reprint Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study
    Stefano Ferrari
    Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Tumori 96:213-8. 2010
    ..To investigate a six-drug combination in patients with nonmetastatic Ewing sarcoma, focusing on chemotherapy-induced necrosis and chemotherapy toxicity in adult and pediatric patients...
  7. doi request reprint Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience
    Gaetano Bacci
    Chemotherapy Unit, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:908-12. 2008
    ..20%). The authors conclude that there does not seem to be any indication to treat preadolescent primary high-grade nonmetastatic osteosarcoma patients by alternative and/or more aggressive therapies...
  8. doi request reprint Periosteal osteosarcoma: a single-institution experience
    Marilena Cesari
    Chemotherapy Section, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 117:1731-5. 2011
    ..The objective of this study was to review and analyze the clinical and treatment-related factors that influence the survival of patients with periosteal osteosarcoma who received treatment in a single institution...
  9. doi request reprint Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years
    Stefano Ferrari
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, Italy
    Tumori 98:702-8. 2012
    ..Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30-40 years...
  10. doi request reprint Local and systemic control of Ewing's bone sarcoma family tumors of the ribs
    Antonio Briccoli
    Unit of General Surgery, Istituto Ortopedico Rizzoli, Bologna 40136, Italy
    J Surg Oncol 100:222-6. 2009
    ..A retrospective analysis of the results and relapse pattern was evaluated in 34 patients with Ewing's family bone tumors (EFBT) treated at Rizzoli Institute with neoadjuvant chemotherapy between 1983 and 2003...
  11. doi request reprint Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy
    Claudia Maria Hattinger
    Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Bologna, Italy
    Histopathology 67:338-47. 2015
    ..To evaluate the clinical impact of excision repair cross-complementation group 1 (ERCC1) expression in high-grade osteosarcoma (OS)...
  12. doi request reprint High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Surg Oncol 98:415-20. 2008
    ..Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy...
  13. doi request reprint Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy
    Gaetano Bacci
    Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    Radiother Oncol 93:383-7. 2009
    ..Local treatment for non-metastatic Ewing's sarcoma family tumors (ESFTs) is controversial. Results achieved in a single institution in patients with ESFT of the humerus are presented...
  14. doi request reprint The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian Rizzoli experience. Impact on the future
    Stefano Ferrari
    Sezione di Chemioterapia, dei Tumori dell Apparato Locomotore, Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy
    Cancer Treat Res 152:275-87. 2009
    ..Collaborative projects with international groups and institutions are crucial for this rare disease...
  15. doi request reprint Spontaneous regression of lung metastasis from osteosarcoma: a case report
    Gaetano Bacci
    Division of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 30:90-2. 2008
    ..The patient was followed up every 3 months and a spontaneous regression of the lesion was documented. Seven years after the diagnosis of lung metastases, no pulmonary nodules or other signs of relapse are present...
  16. ncbi request reprint Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution
    Marilena Cesari
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    Tumori 93:423-7. 2007
    ..Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute...
  17. ncbi request reprint Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma
    Stefano Ferrari
    Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy
    Pediatr Blood Cancer 50:752-6. 2008
    ..Ezrin is a membrane-cytoskeleton linker protein involved in regulating growth and metastatic behaviour of cancer cells. The study evaluated ezrin expression and its prognostic value in patients with non-metastatic osteosarcoma...
  18. doi request reprint Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1
    Stefano Ferrari
    Istituto Ortopedico Rizzoli, Bologna, Italy
    J Clin Oncol 30:2112-8. 2012
    ..We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity...
  19. ncbi request reprint Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma
    Stefano Ferrari
    Chemotherapy, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 29:364-8. 2007
    ..003). Female were more likely to achieve a GR (F 64% vs. M 42%, P<0.02). After multivariate analysis sex and age retained statistical significance. Age and sex influence the histologic response in patients with Ewing sarcoma...
  20. doi request reprint Imaging in bone sarcomas. The chemotherapist's point of view
    Stefano Ferrari
    Chemotherapy, Bone Tumor Center, Istituto Ortopedico Rizzoli, Bologna, Italy Electronic address
    Eur J Radiol 82:2076-82. 2013
    ..Innovative approaches aiming to evaluate vascular and metabolic response rather than mono- or bi-dimensional changes may be more informative and require further investigations. ..
  21. doi request reprint CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases
    Marco Gambarotti
    Department of Pathology, Rizzoli Institute, Bologna, Italy
    Histopathology 69:624-34. 2016
    ..Round-cell sarcomas lacking specific translocations represent a diagnostic challenge. The aim of this study was to describe seven cases of CIC-DUX4 fusion-positive sarcomas, including the first reported example arising primarily in bone...
  22. pmc Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions
    Emanuela Palmerini
    Departments of Chemotherapy Orthopaedic Surgery Surgical Pathology Research Laboratory, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Bologna, Italy Departments of Medicine Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
    Am J Clin Oncol 37:528-34. 2014
    ..The literature regarding treatment and outcome of patients with this tumor is limited.We performed a 2 institutional retrospective study to analyze treatment and survival of patients with angiosarcoma of bone...
  23. ncbi request reprint Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
    Gaetano Bacci
    Chemotherapy, Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Pediatr Hematol Oncol 28:774-80. 2006
    ..0.8%, P<0.009). Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented...
  24. doi request reprint Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Bologna, Italy
    Eur J Cancer 51:210-7. 2015
    ..Tenosynovial giant cell tumour/pigmented villonodular synovitis (TGCT/PVNS) is a benign neoplasm of synovium and tendon sheath. We conducted a retrospective pooled analysis in three major referral centers...
  25. ncbi request reprint Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
    Stefano Ferrari
    Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy
    Curr Opin Oncol 19:341-6. 2007
    ..The most recent developments regarding chemotherapy treatment of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical trials and evaluations of late effects of chemotherapy...
  26. doi request reprint Analysis of risk factors for central venous catheter-related complications: a prospective observational study in pediatric patients with bone sarcomas
    Massimo Eraldo Abate
    Author Affiliations Department of Chemotherapy Dr Abate, Ms Boschi, Ms Raspanti, Dr Cesari, Dr Paioli, Dr Palmerini, Dr Ferrari, Radiology Section Ms Loro, and Ultrasound Section Dr Affinito, Istituto Ortopedico Rizzoli, Bologna, Italy and Pediatric Oncology Unit Dr Escobosa Sánchez, Carlos Haya Hospital, Malaga, Spain
    Cancer Nurs 37:292-8. 2014
    ..The analysis of risk factors is part of the strategy to reduce the incidence of CVC complications...
  27. doi request reprint Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers
    Stefano Radaelli
    Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of Orthopedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy Department of Medical Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy Laboratory of Methodology for Biomedical Research, Oncology Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Department of Vertebral Oncologic Surgery, Istituto Ortopedico Rizzoli, Bologna, Italy Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
    Spine (Phila Pa 1976) 41:1049-57. 2016
    ..Retrospective case series...
  28. doi request reprint Diagnosis and prognosis for the Ewing family of tumors
    Emanuela Palmerini
    Istituto Ortopedico Rizzoli, Department of Musculoskeletal Oncology, Via Pupilli 1, 40136 Bologna, Italy 39 051 6366 829 39 051 6366 277
    Expert Opin Med Diagn 3:445-52. 2009
    ..This percentage is no more than 20 - 25% for patients with metastatic disease at presentation...
  29. doi request reprint Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives
    Eric L Staals
    Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy Electronic address
    Eur J Cancer 63:34-40. 2016
    ..Clinical trials of agents that target D-TGCT are currently ongoing. In the meantime, international registries should be activated in order to provide useful information on this relatively rare tumour. ..
  30. doi request reprint Emerging therapeutic targets for synovial sarcoma
    Emanuela Palmerini
    Chemotherapy, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Expert Rev Anticancer Ther 14:791-806. 2014
    ..This review will summarize achievements and pitfalls of drugs against emerging therapeutic targets for synovial sarcoma. ..